Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families.

Read more

 
Nov 16, 2017
Corium Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Corporate Highlights
MENLO PARK, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the fourth fiscal quarter and the year ended September 30, 201…


Nov 9, 2017
Corium to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, November 16, 2017
MENLO PARK, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) — Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the fourth quarter and fiscal year ended September 30, 2017 on Thursday, November 16, 2017 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcas…

OUR LEAD PRODUCT

CorplexTM Donepezil

A once-weekly treatment for Alzheimer’s disease, our lead product is a transdermal formulation of donepezil, the active ingredient in Aricept®, which is one of the most commonly prescribed treatments for the care of patients with Alzheimer’s disease. We have demonstrated sustained and controlled delivery of donepezil over a one-week period, with a pharmacokinetic (PK) profile comparable to oral Aricept taken daily for seven days. Learn more

circle_couple2